Cantex Pharmaceuticals

CompanyUnited States

Cantex Pharmaceuticals develops one asset, in phase 1 (azeliragon in glioblastoma). Mostly small molecule acting on AGER; based in the United States.

1
Asset
Furthest stage
Phase 1
2
Trials
1
Signal

Pipeline

1
  • azeliragon

    Inhibits the receptor for advanced glycation end products, suppressing inflammatory signaling.

    Phase 1, Small molecule, AGER, glioblastoma

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials9
  • Signals2
  • Similar companies6

Intelligence